More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

BACKGROUND: Ethiopia was using the ChAdOx1 COV-19 vaccine, and health professionals were targets of the first phase of the vaccination strategy. Evidence on the adverse events following immunization (AEFI) was barely available. The study aimed to assess the magnitude and associated factors of advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Muluneh, Atalay Goshu, Merid, Mehari Woldemariam, Gelaye, Kassahun Alemu, Tilahun, Sewbesew Yitayih, Teshager, Nahom Worku, Abereha, Aklilu Yiheyis, Sugamo, Kalkidan Samuel, Yimer, Mulugeta Ayalew, Kassa, Getahun Molla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078864/
https://www.ncbi.nlm.nih.gov/pubmed/35535029
http://dx.doi.org/10.2147/IDR.S360605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078864/
https://www.ncbi.nlm.nih.gov/pubmed/35535029
http://dx.doi.org/10.2147/IDR.S360605

Ejemplares similares